View article

The clinical landscape of lymphomas has changed dramatically over the last 2 decades, including significant progress made in the understanding and utilization of imaging modalities and the available treatment options for both indolent and aggressive lymphomas. Since the introduction of hybrid PET/CT scanners in 2001, the indications of 18Ffluoro-deoxyglucose (FDG) PET/CT in the management of lymphomas have grown rapidly. In today’s clinical practice, FDG PET/CT is used in successful management of the vast majority patients with lymphomas.

In this review, the authors start with providing a historical overview of management of lymphomas from a diagnostic imaging perspective, describing how FDG-PET/CT was integrated in the management algorithm. The subsequent sections elaborate on the clinical indications of performing FDG-PET/CT in patients with lymphoma, describing the currently followed …